Table 1.

Associations between SNPs in the fatty acid pathways and NSCLC risk with FDR-P<0.05

SNP	Gene	Chr	Position	Allele*	TRICL							Harvard
					EAF	Q†	I2	Effects ‡	OR (95%CI)	P	FDR	EAF	OR (95%CI)	P
rs1800628	TNF	6	31546850	G/A	0.11	0.541	0	++++++	1.18 (1.11–1.24)	5.46×10−9	0.0002	0.09	1.14 (0.99–1.32)	0.071
rs4646521	CYP4F3	19	15769872	G/T	0.35	0.672	0	++++++	1.09 (1.05–1.13)	3.83×10−6	0.018	0.37	0.99 (0.91–1.07)	0.774
rs10405638	CYP4F3	19	15764870	C/T	0.36	0.478	0	++++-+	1.09 (1.05–1.12)	7.59×10−6	0.018	0.38	0.99 (0.92–1.08)	0.888
rs4646904§	CYP4F3	19	15763721	G/A	0.36	0.488	0	++++-+	1.09 (1.05–1.13)	8.65×10−6	0.018	0.37	0.99 (0.92–1.08)	0.884
rs2102959	CYP4F3	19	15767392	A/G	0.36	0.573	0	++++-+	1.08 (1.05–1.12)	1.07×10−5	0.018	0.38	0.99 (0.91–1.07)	0.779
rs10401516	CYP4F3	19	15760577	C/T	0.36	0.552	0	++++-+	1.08 (1.05–1.12)	1.17×10−5	0.018	0.38	0.99 (0.92–1.08)	0.895
rs4646514	CYP4F3	19	15769270	A/C	0.36	0.562	0	++++-+	1.08 (1.04–1.12)	1.27×10−5	0.018	0.38	0.98 (0.90–1.06)	0.633
rs4646515	CYP4F3	19	15769379	G/C	0.36	0.562	0	++++-+	1.08 (1.04–1.12)	1.27×10−5	0.018	0.38	0.98 (0.90–1.06)	0.615
rs718258	CYP4F3	19	15766419	G/A	0.36	0.564	0	++++-+	1.08 (1.04–1.12)	1.28×10−5	0.018	0.38	0.99 (0.91–1.07)	0.807
rs4646520	CYP4F3	19	15769775	A/G	0.36	0.558	0	++++-+	1.08 (1.04–1.12)	1.33×10−5	0.018	0.38	0.98 (0.90–1.06)	0.599
rs10404163	CYP4F3	19	15769805	A/T	0.36	0.558	0	++++-+	1.08 (1.04–1.12)	1.33×10−5	0.018	0.38	0.98 (0.90–1.06)	0.599
rs4646513	CYP4F3	19	15769253	C/A	0.36	0.561	0	++++-+	1.08 (1.04–1.12)	1.34×10−5	0.018	0.38	0.98 (0.90–1.06)	0.639
rs2073600	CYP4F3	19	15757643	C/T	0.36	0.475	0	++++-+	1.08 (1.04–1.12)	1.51×10−5	0.018	0.37	1.00 (0.92–1.08)	0.983
rs2072598	CYP4F3	19	15757528	A/G	0.36	0.472	0	++++-+	1.08 (1.04–1.12)	1.53×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs2280750	CYP4F3	19	15757428	T/A	0.36	0.473	0	++++-+	1.08 (1.04–1.12)	1.54×10−5	0.018	0.37	1.00 (0.92–1.08)	0.992
rs2283611	CYP4F3	19	15759828	A/G	0.36	0.461	0	++++-+	1.08 (1.04–1.12)	1.54×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs2283609	CYP4F3	19	15759764	C/T	0.36	0.462	0	++++-+	1.08 (1.04–1.12)	1.54×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs2077040	CYP4F3	19	15755840	T/C	0.36	0.474	0	++++-+	1.08 (1.04–1.12)	1.55×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs2077080	CYP4F3	19	15755392	G/C	0.36	0.474	0	++++-+	1.08 (1.04–1.12)	1.55×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs4808346	CYP4F3	19	15758931	T/C	0.36	0.462	0	++++-+	1.08 (1.04–1.12)	1.55×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs8107976	CYP4F3	19	15753683	A/G	0.36	0.481	0	++++-+	1.08 (1.04–1.12)	1.55×10−5	0.018	0.37	1.00 (0.92–1.08)	0.988
rs2203998	CYP4F3	19	15754893	A/G	0.36	0.477	0	++++-+	1.08 (1.04–1.12)	1.56×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs8106799	CYP4F3	19	15753759	G/A	0.36	0.48	0	++++-+	1.08 (1.04–1.12)	1.56×10−5	0.018	0.37	1.00 (0.92–1.08)	0.990
rs2204000	CYP4F3	19	15755112	G/A	0.36	0.479	0	++++-+	1.08 (1.04–1.12)	1.56×10−5	0.018	0.37	1.00 (0.92–1.08)	0.986
rs2203999	CYP4F3	19	15754975	C/T	0.36	0.479	0	++++-+	1.08 (1.04–1.12)	1.56×10−5	0.018	0.37	1.00 (0.92–1.08)	0.986
rs4646512	CYP4F3	19	15764220	C/T	0.36	0.454	0	++++-+	1.08 (1.04–1.12)	1.58×10−5	0.018	0.38	1.00 (0.92–1.08)	0.948
rs116260720	GPX5	6	28502794	C/A	0.22	0.335	12.5	+++++-	1.10 (1.05–1.14)	1.65×10−5	0.018	0.21	1.11 (1.00–1.22)	0.043
rs4646516	CYP4F3	19	15769449	A/G	0.36	0.568	0	++++-+	1.08 (1.04–1.12)	1.67×10−5	0.018	0.38	0.98 (0.90–1.06)	0.639

NSCLC: non-small cell lung cancer; EAF, effect allele frequency; FDR, false discovery rate; TRICL, Transdisciplinary Research in Cancer of the Lung;

^*reference allele / effect allele;

^†fixed effect models were used when no heterogeneity was found between studies (Q>0.10 and I² <25.0%); otherwise, random effect models were used;

^‡means positive association, and-means negative association;

^§online function prediction tool, SNPinfo [25], found that rs4646904 might influence splicing efficiency of CYP4F3;

SNPs in bold were putative functional and were not located in the major histocompatibility complex region.